ScreenerHero
AGYAllergy Therapeutics plc
LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · allergytherapeutics.com
5.372GBP+2.32%Mkt Cap: 426.41M $P/E: —

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap426.41M $
Enterprise Value434.92M $
Revenue (TTM)73.49M $
Gross Profit37.58M $
Net Income (TTM)-51.47M $
Revenue/Share0.0141 USD
Last Price5.372 GBP
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees584
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.46
PEG—
EV/EBITDA-10.73
EV/Revenue5.92
P/S5.94
P/B53.72
EPS (TTM)-0.01
EPS (Forward)-0.01
52W Range
0.000044% of range12.10
52W High12.10 GBP
52W Low0.0000 GBP
Profitability
Gross Margin53.23%
Oper. Margin-31.35%
EBITDA Margin-55.16%
Profit Margin-72.91%
ROE142.35%
ROA-59.42%
Growth
Revenue Growth6.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.05M $
CapEx (TTM)4.39M $
FCF Margin-42.18%
FCF Yield-7.27%
Net Debt21.38M $
Net Debt/EBITDA-0.53
Balance Sheet
Debt/Equity-2.13
Current Ratio1.13
Quick Ratio0.70
Book Value/Sh0.0010 GBP
Cash/Share0.0020 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.00 GBP
Upside (mean)+142.0%
Target Range13.00 GBP – 13.00 GBP
# Analysts1
Ownership
Shares Out.6.33B
Float701.66M
Insiders88.78%
Institutions0.01%
Technical
SMA 506.348 (-15.4%)
SMA 2009.525 (-43.6%)
Beta0.83
S&P 52W Chg18.16%
Avg Vol (30d)199.13K
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)39.6
MACD-0.4466
MACD Signal-0.4997
MACD Hist.+0.0532
BB Upper6.424 GBP
BB Middle5.564 GBP
BB Lower4.705 GBP
BB Width30.89%
ATR (14)0.6843 GBP
Vol Ratio (20d)0.10x